Cipla: Margins disappoint again - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cipla: Margins disappoint again

Jan 21, 2002

Pharma major, Cipla has declared encouraging sales growth of 33% for 3QFY02 which is more or less in line with the street's expectations. However, a sharp slide in operating margins has come as a major disappointment from the company.

(Rs m)3QFY013QFY02Change
Sales 2,756 3,663 32.9%
Other Income 82 153 86.9%
Expenditure 2,070 2,942 42.2%
Operating Profit (EBDIT) 687 720 4.9%
Operating Profit Margin (%)24.9%19.7% 
Interest 3 8 169.0%
Depreciation 40 49 21.3%
Profit before Tax 725 817 12.6%
Other Adjustments - -  
Tax 190 190 0.0%
Profit after Tax/(Loss) 535 627 17.0%
Net profit margin (%)19.4%17.1% 
No. of Shares (eoy) (m) 60.0 60.0  
Diluted Earnings per share 35.7 41.8 
P/E (at current price) 28 

Though we were expecting a drop in margins, a 520 basis points slide comes as a surprise especially with increasing contribution from export revenues. This is third quarter in a row, that Cipla has recorded a drop in operating margins. The drop seems to be on the back of rising marketing expenses.

3QFY02: Projected vs. Actuals
ParticularsActualsProjected% Change
Total Sales (Rs. m)36633,6081.52%
Operating Profit720779-7.61%
Operating Margins (%)19.721.6NA
Net Profit (Rs. m)62767125.40%

Exports seem to have recorded a healthy growth of 75-80% in line with our expectations. Domestic sales also seem to have grown in line with expectations (13-14%). The company has already started exporting bulk Omeprazole to Andrx. Considering the fact that generic launch by Andrx is expected only in June’02, it is expected to stock up 4-5 months ahead of its launch. The fourth quarter of the current year should see considerable revenue contribution from export of Omeprazole bulk by Cipla. We are expecting Omeprazole export revenues of Rs 677 m (US$ 14 m) in the current year. There is still uncertainty with regard to timing of exports of CFC free inhalers to European and anti-AIDS drugs to the South African markets.

Though insignificant on the net basis, interest burden has gone up sharply in last couple of quarters. This could be due to borrowings by the company for setting up its new formulations plant in Goa at a cost of Rs 1.2 bn. Depreciation expenses also seem to have gone up on that account. However, the company is expected to save on tax outgo due to commencement of the new Goa plant.

At the current market price of Rs 1,168, the stock trades at a P/e of 28 x annualised earnings. Considering a sharp fall in operating margins, we would be revising our earnings estimates downwards. The stock might see selling pressure due to initial disappointment.

Equitymaster requests your view! Post a comment on "Cipla: Margins disappoint again". Click here!

  

More Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

CIPLA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 20, 2021 | Updated on Oct 20, 2021

Here's an analysis of the annual report of CIPLA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Dec 7, 2021 01:45 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS